Cecal Perforation in a COVID-19 Patient Treated with Tocilizumab: A Case Report
| Autor: | Victor Dominguez Prieto, Cecilia Meliga, Sara Rosenstone, Siyuan Qian Zhang, Manuel Escanciano Escanciano, Felipe Velez Pinto, Sergio Hernandez Villafranca, Sara Gonzalez Soares, Javier Barambio Buendia, Miguel Leon Arellano, Damian Garcia Olmo, Ricardo Pardo Garcia, Hector Guadalajara Labajo |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
musculoskeletal diseases
medicine.medical_specialty Lung biology business.industry Perforation (oil well) Context (language use) medicine.disease Gastroenterology chemistry.chemical_compound Pneumonia medicine.anatomical_structure Immune system Tocilizumab chemistry Gastrointestinal perforation Internal medicine medicine biology.protein skin and connective tissue diseases Interleukin 6 business |
| Zdroj: | Surgical Case Reports. :1-3 |
| ISSN: | 2613-5965 |
| DOI: | 10.31487/j.scr.2021.08.21 |
| Popis: | Tocilizumab is a monoclonal antibody against the interleukin-6 receptor. Gastrointestinal perforation has been associated with Tocilizumab treatment. In the absence of specific antiviral drugs, Tocilizumab is currently being used as a treatment option in patients with severe COVID-19 pneumonia. This is being based on the implication of interleukin-6 in the aberrant host immune response that characterizes the disease and initiates patients' lung damage. Herein we present the case of a cecal perforation in a patient treated with Tocilizumab for COVID-19. In such context, we expect that there may be an increase in the incidence of gastrointestinal perforation related to Tocilizumab. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|